Our results showed significant down-regulation of phase I (e.g. CYP3A11), phase II (e.g. GSTa2) DMEs and upregulation of drug transporters (e.g. MDR1 and MRP3) in hepatic cancer tissues (Fig 2 and Figure B in S1 File). The gene discussed is GSTA2; the disease is liver cancer.